***Title:***

**Obesity is a risk factor for greater** **COVID-19 severity**

Feng Gao1#, Kenneth I. Zheng2#, Xiao-Bo Wang3, Qing-Feng Sun4, Ke-Hua Pan5, Ting-Yao Wang6, Giovanni Targher7, Christopher D. Byrne8, Jacob George9 and Ming-Hua Zheng2,10,11\*

1Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;

2NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;

3Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China;

4Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China;

5Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;

6Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;

7Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy;

8Southampton National Institute for Health Research Biomedical Research Centre, University Hospital Southampton, Southampton General Hospital, Southampton, UK;

9Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia;

10Institute of Hepatology, Wenzhou Medical University, Wenzhou, China;

11Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China.

#**Co-first author**: Feng Gao and Kenneth I. Zheng

**\*Corresponding Author:**

Ming-Hua Zheng, MD, PhD

NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University; No. 2 Fuxue Lane, Wenzhou 325000, China.

E-mail: zhengmh@wmu.edu.cn; fax: (86) 577-55578522; tel: (86) 577-55579622.

**List of Abbreviations**

BMI, body mass index; CI, confidence intervals; COVID-19, coronavirus disease-2019; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome-associated coronavirus 2; T2DM, type 2 diabetes mellitus.

**Authors Contributions**

Study concept and design: Feng Gao, Kenneth I. Zheng and Ming-Hua Zheng

Acquisition of data: Xiao-Bo Wang, Qing-Feng Sun, Ke-Hua Pan and Ting-Yao Wang

Analysis and interpretation of data: Fen Gao and Kenneth I. Zheng

Drafting of the manuscript: Feng Gao and Kenneth I. Zheng

Critical revision of the manuscript for important intellectual content: Giovanni Targher, Christopher D. Byrne and Jacob George

Study supervision: Ming-Hua Zheng

All authors contributed to the manuscript for important intellectual contents and approved the submission.

**Guarantor of the article:** Ming-Hua Zheng

**Acknowledgments**

The authors thank Hong-Lei Ma (NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China) and Wen-Yue Liu (Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China) for data collection.

**Conflict of Interest Statement**

All authors: nothing to declare.

**Funding sources:**

This work was supported by grants from the National Natural Science Foundation of China (81500665), funding of the Ruian Science and Technology Bureau (2020023), High Level Creative Talents from Department of Public Health in Zhejiang Province and Project of New Century 551 Talent Nurturing in Wenzhou. GT is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. CDB is supported in part by the Southampton NIHR Biomedical Research Centre (IS-BRC-20004), UK.

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention ([1](#_ENREF_1)). Obesity commonly aggravates the severity of respiratory diseases, but it is currently not known whether obese patients are also more likely to have greater COVID-19 severity of illness. We investigated the association between obesity and COVID-19 severity of illness among patients with laboratory-confirmed SARS-CoV-2 infection.

We enrolled adult patients with COVID-19 from three hospitals in China between 1st January 2020 and 29th February 2020. Seventy-five patients were diagnosed as obese (i.e. cases). We randomly matched each case with one control (non-obesity) by sex (1:1) and age (±5 years). The cohort thus comprised 150 patients with COVID-19. The study protocol was approved by local ethics committees of the three hospitals. The requirement for written informed consent was waived due to the retrospective and anonymous nature of the study.

COVID-19 was diagnosed as a positive result by high-throughput sequencing or real-time reverse transcriptase-polymerase chain reaction assay of oropharyngeal swab specimens. COVID-19 severity of illness was assessed during hospitalization and classified into four clinical subtypes (i.e. mild, moderate, severe or critically-ill) based on management guidelines ([2](#_ENREF_2)). Obesity was defined as a body mass index (BMI) ≥25 kg/m2 in this Asian population. Diabetes was determined as either history of diagnosed diabetes, use of anti-diabetic drugs, or, in few cases, newly diagnosed diabetes after recovery from acute SARS-CoV-2 infection. Diagnosis of diabetes was made using standard procedures at the three hospitals, based on guidelines of the China Diabetes Prevention and Control recommendations ([3](#_ENREF_3)). Hypertension and dyslipidemia were diagnosed based on established criteria. All patients denied a history of active cancer, chronic obstructive or restrictive pulmonary diseases, or other end-stage diseases. Patients received standard treatments according to the Chinese COVID-19 management guidance (7th edition) ([2](#_ENREF_2)), and were all discharged alive from hospital.

For statistical purpose, COVID-19 patients were categorized into two groups according to their disease severity as non-severe (i.e., mild and moderate disease, combined) and severe (severe and critical, combined) ([2](#_ENREF_2)). The association between presence of obesity or increasing BMI values (as exposure measures) and COVID-19 severity (as the outcome measure) was assessed by binary logistic regression analysis. Statistical analyses were two-sided and significance was set at *p*<0.05.

The mean age of patients was 48 years and 62.7% were male. Twenty-nine patients (19.3%) had diabetes; obese patients were more likely to have diabetes than those without obesity (24.0% vs. 14.7%). Mean BMIs for non-obese and obese patients were 21.8±2.3 and 27.7±2.7 kg/m2, respectively. At their hospital admission, obese patients had higher levels of plasma C-reactive protein and lower lymphocyte counts, which are considered two early indicators of severe COVID-19 ([2](#_ENREF_2)). Notably, obese patients also had a longer hospital stay (median 23 [IQR 17-30] vs. 18 [13-24] days; *p*=0.037) and a greater proportion had severe COVID-19 (33.3% vs. 14.7%, *p*=0.007 by the chi-squared test; **Figure 1A**), compared to non-obese patients. As shown in **Figure 1B**, there was a clear dose-effect relationship between increasing values of BMI and the proportion of patients with severe COVID-19.

In the logistic regression analyses, the presence of obesity was associated with a ~threefold increased risk of having severe COVID-19 (unadjusted-OR 2.91, 95%CI 1.31-6.47). Each one-unit increase in BMI was also associated with a 12% increase in the risk of severe COVID-19 (unadjusted-OR 1.12, 95%CI 1.01-1.23). Notably, the association between obesity (or increasing BMI values) and greater COVID-19 severity remained significant even after adjusting for age, sex, smoking status, hypertension, diabetes and dyslipidemia (adjusted-OR 3.00, 95%CI 1.22-7.38 for obesity, and adjusted-OR 1.13, 95%CI 1.01-1.28 for BMI, respectively).

To date, the virologic and physiological mechanisms underlying the strong relationship we observed between obesity and COVID-19 severity are poorly understood. It is plausible to hypothesize that more severe COVID-19 in patients with obesity may be the consequence of underlying low-grade chronic inflammation, and suppression of innate and adaptive immune responses ([4](#_ENREF_4)). In addition, the altered microenvironment associated with obesity may support a more diverse viral quasispecies and affords the emergence of potentially pathogenic variants capable of inducing greater disease severity ([5](#_ENREF_5)). Finally, mechanical dysfunction due to severe obesity may increase the severity of lower respiratory tract infection and contribute to secondary infection ([6](#_ENREF_6)).

Health care professionals caring for COVID-19 patients should be cognizant of the increased likelihood of severe COVID-19 in obese patients. In particular, the presence of obesity increases the risk of severe illness approximately three-fold with a consequent longer hospital stay.

**REFERENCES**

1. WHO characterizes COVID-19 as a pandemic. Published March 13, 2020. Accessed March 18, 2020. https://[www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen;](http://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen)

2. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). 2020 [EB/OL]. 2020.03.03;

3. Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition). Chinese Journal of Diabetes Mellitus 2018;10:4-67

4. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. The Journal of clinical investigation 2017;127:1-4

5. Honce R, Karlsson EA. Obesity-Related Microenvironment Promotes Emergence of Virulent Influenza Virus Strains. 2020;11

6. Dixon AE, Peters U. The effect of obesity on lung function. Expert review of respiratory medicine 2018;12:755-767

**LEGEND TO THE FIGURE**

**Figure 1.** (A) Prevalence of clinical subtypes of COVID-19 severity amongst infected patients with and without obesity, and (B) association between increasing BMI values and COVID-19 severity.